Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Inclusion Criteria: * is healthy, based on screening safety laboratory, medical history, and physical examination results * is a pre-term infant (born at 29 weeks to 35 weeks gestational age \[inclusive\]) or a full-term infant (born at over 35 weeks gestational age), as confirmed in medical records * weighs ≥2 kg at screening Exclusion Criteria: * has been recommended to receive palivizumab per local standard of care * has ≥1 documented out-of-range safety laboratory results (adjusted for age) at the time of screening * has a known hypersensitivity to any component of the respiratory syncytial virus (RSV) monoclonal antibody * has a history of congenital or acquired immunodeficiency (e.g., splenomegaly) * has documented human immunodeficiency virus (HIV) infection, hepatitis B (HBsAg positive), or hepatitis C (HCV ribonucleic acid \[RNA\] positive) * has known history of functional or anatomic asplenia * has a diagnosis of failure to thrive within 14 days of screening * has known or history of a coagulation disorder contraindicating intramuscular injection * has received or is expected to receive blood products (except irradiated platelets) within 3 months prior to enrollment * has prior known documented RSV infection * has hemodynamically significant congenital heart disease * has chronic lung disease of prematurity requiring ongoing medical therapy * has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that, in the opinion o…